CR20230211A - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas - Google Patents
Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetasInfo
- Publication number
- CR20230211A CR20230211A CR20230211A CR20230211A CR20230211A CR 20230211 A CR20230211 A CR 20230211A CR 20230211 A CR20230211 A CR 20230211A CR 20230211 A CR20230211 A CR 20230211A CR 20230211 A CR20230211 A CR 20230211A
- Authority
- CR
- Costa Rica
- Prior art keywords
- factor receptor
- cyclopentathiophene
- activating factor
- platelet activating
- receptor antagonists
- Prior art date
Links
- 108700023400 Platelet-activating factor receptors Proteins 0.000 title abstract 2
- 102000030769 platelet activating factor receptor Human genes 0.000 title abstract 2
- ADEGUPDGFKUYII-UHFFFAOYSA-N 2H-cyclopenta[b]thiophene-2-carboxamide Chemical class S1C=2C(=CC1C(=O)N)C=CC=2 ADEGUPDGFKUYII-UHFFFAOYSA-N 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Ciclopentatiofen carboxamidas de la Fórmula (I.0)en donde R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> y n son como se definen en la descripción y las reivindicaciones, y las sales de este aceptables desde el punto de vista farmacéutico pueden usarse en métodos para el tratamiento de enfermedades que pueden estar influenciadas por antagonizar la actividad mediada por el receptor del factor de activación de plaquetas. <img alt="" src="data:image/png;base64,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 (***)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207719 | 2020-11-16 | ||
| PCT/EP2021/081459 WO2022101377A1 (en) | 2020-11-16 | 2021-11-12 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230211A true CR20230211A (es) | 2023-07-13 |
Family
ID=73543025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230211A CR20230211A (es) | 2020-11-16 | 2021-11-12 | Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11766443B2 (es) |
| EP (1) | EP4244229A1 (es) |
| JP (2) | JP7465368B2 (es) |
| KR (1) | KR20230109692A (es) |
| CN (2) | CN117624188A (es) |
| AR (1) | AR124070A1 (es) |
| AU (1) | AU2021379248A1 (es) |
| CA (1) | CA3200710A1 (es) |
| CL (2) | CL2023001361A1 (es) |
| CO (1) | CO2023005894A2 (es) |
| CR (1) | CR20230211A (es) |
| DO (1) | DOP2023000090A (es) |
| EC (1) | ECSP23036210A (es) |
| IL (1) | IL302769A (es) |
| MX (1) | MX2023005678A (es) |
| TW (1) | TW202237620A (es) |
| WO (1) | WO2022101377A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3502392A1 (de) | 1985-01-25 | 1986-07-31 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen |
| PH30676A (en) | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
| DE3909012A1 (de) | 1989-03-18 | 1990-09-20 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| DE4132763A1 (de) | 1991-10-02 | 1993-04-08 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US20050032713A1 (en) * | 2002-03-27 | 2005-02-10 | Wurtman Richard J. | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents |
| AU2007321920A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterotricyclic metalloprotease inhibitors |
-
2021
- 2021-11-12 AU AU2021379248A patent/AU2021379248A1/en active Pending
- 2021-11-12 CA CA3200710A patent/CA3200710A1/en active Pending
- 2021-11-12 CR CR20230211A patent/CR20230211A/es unknown
- 2021-11-12 CN CN202311341729.0A patent/CN117624188A/zh active Pending
- 2021-11-12 WO PCT/EP2021/081459 patent/WO2022101377A1/en active Application Filing
- 2021-11-12 JP JP2022562298A patent/JP7465368B2/ja active Active
- 2021-11-12 MX MX2023005678A patent/MX2023005678A/es unknown
- 2021-11-12 IL IL302769A patent/IL302769A/en unknown
- 2021-11-12 EP EP21806745.2A patent/EP4244229A1/en active Pending
- 2021-11-12 CN CN202180076849.5A patent/CN116745300A/zh active Pending
- 2021-11-12 US US17/524,759 patent/US11766443B2/en active Active
- 2021-11-12 KR KR1020237020295A patent/KR20230109692A/ko unknown
- 2021-11-15 TW TW110142333A patent/TW202237620A/zh unknown
- 2021-11-15 AR ARP210103159A patent/AR124070A1/es unknown
-
2023
- 2023-05-08 CO CONC2023/0005894A patent/CO2023005894A2/es unknown
- 2023-05-11 CL CL2023001361A patent/CL2023001361A1/es unknown
- 2023-05-11 DO DO2023000090A patent/DOP2023000090A/es unknown
- 2023-05-17 EC ECSENADI202336210A patent/ECSP23036210A/es unknown
- 2023-07-14 US US18/221,936 patent/US20230355638A1/en active Pending
-
2024
- 2024-02-01 CL CL2024000317A patent/CL2024000317A1/es unknown
- 2024-03-29 JP JP2024055696A patent/JP2024099528A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024099528A (ja) | 2024-07-25 |
| ECSP23036210A (es) | 2023-06-30 |
| US20230355638A1 (en) | 2023-11-09 |
| WO2022101377A1 (en) | 2022-05-19 |
| US20220160725A1 (en) | 2022-05-26 |
| JP2023521200A (ja) | 2023-05-23 |
| KR20230109692A (ko) | 2023-07-20 |
| CL2024000317A1 (es) | 2024-07-12 |
| AR124070A1 (es) | 2023-02-08 |
| CL2023001361A1 (es) | 2023-11-03 |
| US11766443B2 (en) | 2023-09-26 |
| TW202237620A (zh) | 2022-10-01 |
| EP4244229A1 (en) | 2023-09-20 |
| CN116745300A (zh) | 2023-09-12 |
| MX2023005678A (es) | 2023-05-26 |
| CA3200710A1 (en) | 2022-05-19 |
| AU2021379248A1 (en) | 2023-06-22 |
| CN117624188A (zh) | 2024-03-01 |
| IL302769A (en) | 2023-07-01 |
| JP7465368B2 (ja) | 2024-04-10 |
| DOP2023000090A (es) | 2023-06-15 |
| AU2021379248A9 (en) | 2024-10-10 |
| CO2023005894A2 (es) | 2023-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501140A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
| PH12017502425A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| TN2019000110A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| MX2018009257A (es) | Derivados de benzimidazol como moduladores de ror-gamma. | |
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| PH12021551196A1 (en) | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| MX2021002321A (es) | Nuevos metodos. | |
| MX2016013908A (es) | Novedoso compuesto de 1,2,4-triazina disustituida. | |
| MX2021010888A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis. | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| MX2022006086A (es) | Derivados de piridopirimidinona como antagonistas de ahr. | |
| MX2020010618A (es) | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. | |
| EA202090383A1 (ru) | Усовершенствованный способ получения производных аминопиримидина | |
| PH12019502462A1 (en) | Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors | |
| MX2024007058A (es) | Derivados de 5,6,7,8-tetrahidro-2,6-naftiridina como terapeuticos contra el cancer. | |
| MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
| MX2018014185A (es) | Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. | |
| CR20230211A (es) | Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas | |
| MX2022012404A (es) | Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. | |
| NZ747797A (en) | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist | |
| MX369548B (es) | Gel oral de un inhibidor de la fosfodiesterasa. |